NEWS & Press Releases

2021

April 14, 2021
OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients

January 26, 2021
OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients

2020

June 2, 2020
OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

March 31, 2020
OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

February 19, 2020
OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020

January 7, 2020
OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

2019

October 15, 2019
OrphoMed to Present at the 2019 BIO Investor Forum

2018

December 18, 2018
OrphoMed Announces Formation of Scientific Advisory Board

April 25, 2018
FDA Grants Fast Track Designation for OrphoMed’s ORP-101 for Treatment of IBS-D

April 23, 2018
OrphoMed Appoints Gary M. Phillips, M.D. as President and Chief Executive Officer

March 26, 2018
OrphoMed featured in Wall Street Journal article on intestinal-focused startups

January 31, 2018
OrphoMed to Present at the 2018 BIO CEO & Investor Conference 

2017

October 16, 2017
OrphoMed to Present at the 2017 BIO Investor Forum

MAY 24, 2017
Fierce Biotech: “Takeda and NEA back $39M series A for GI biotech OrphoMed”

MAY 24, 2017
OrphoMed Secures $39 Million Series A Financing Round

MAY 7, 2017
OrphoMed Announces Late-breaking Plenary Session Presentation of New Preclinical Data for ORP-101 in IBS-D at Digestive Disease Week 2017